Melinta Therapeutics

In November 2017, Deerfield committed up to $240 million to Melinta Therapeutics to fund the acquisition of the infectious disease business from The Medicines Company. Melinta is a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections. The products acquired include Vabomere, Orbactiv and Minocin IV.

New American Therapeutics

In the fall of 2010, Deerfield facilitated the creation of New American Therapeutics, a specialty pharmaceutical company run by several former senior executives from Roche and Sanofi-Aventis. Our investment was used to purchase Denavir®, a marketed topical cream for the treatment of cold sores.

Press releases

Deerfield Divests topical herpes drug Denavir to Renaissance Pharmaceuticals
October 2010

Renaissance Pharma Acquires Cold Sore Treatment Denavir®
August 2012